DDInter899 DDInter200
Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell lymphoma (MCL) under accelerated approval; however, in April 2023, the drug manufacturer withdrew the accelerated approvals for ibrutinib in the US. Ibrutinib was approved by the EMA in October 2014 and by Health Canada in November 2014. It is currently approved for the treatment of various conditions, such as chronic lymphocytic leukemia (CLL), Waldenström's Macroglobulinemia, and chronic graft versus host disease (cGVHD) in August 2017. Notably, ibrutinib became the first FDA-approved
Betrixaban is a non-vitamin K oral anticoagulant whose action is driven by the competitive and reversible inhibition of the factor Xa . It was selected among all lead compounds due to its low hERG channel affinity while sustaining its factor Xa inhibition capacity . Betrixaban, now developed by Portola Pharmaceuticals Inc., is prescribed as a venous thromboembolism (VTE) prophylactic for adult patients with moderate to severe restricted motility or with other risks for VTE . VTE can be manifested as deep vein thrombosis or pulmonary embolism and it is a leading cause of preventable death in hospitalized patients .
Betrixaban {u} may cause a minor interaction that can limit clinical effects when taken with {v} Clove
Betrixaban {u} may cause a minor interaction that can limit clinical effects when taken with {v} Turmeric
Betrixaban {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Amprenavir
Betrixaban {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Berotralstat
Betrixaban {u} may lead to a major life threatening interaction when taken with {v} Iloprost
Betrixaban {u} may lead to a major life threatening interaction when taken with {v} Avapritinib
Betrixaban may cause a minor interaction that can limit clinical effects when taken with Clove
Betrixaban may cause a minor interaction that can limit clinical effects when taken with Turmeric
Betrixaban may cause a moderate interaction that could exacerbate diseases when taken with Amprenavir
Betrixaban may cause a moderate interaction that could exacerbate diseases when taken with Berotralstat
Betrixaban may lead to a major life threatening interaction when taken with Iloprost
Betrixaban may lead to a major life threatening interaction when taken with Avapritinib